The TPM3‐NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibitionElena Ardini, Antonella Isacchi, Marcello Gambacorta et al.|Molecular Oncology|2014Cited by 156
Dual Targeting of CDK and Tropomyosin Receptor Kinase Families by the Oral Inhibitor PHA-848125, an Agent with Broad-Spectrum Antitumor EfficacyClara Albanese, Marina Ciomei, Rachele Alzani et al.|Molecular Cancer Therapeutics|2010Cited by 63
The Polo-Like Kinase 1 (PLK1) Inhibitor NMS-P937 Is Effective in a New Model of Disseminated Primary CD56+ Acute Monoblastic LeukaemiaAlessia Casolaro, Rachele Alzani, Josée Golay et al.|PLoS ONE|2013Cited by 34
Anti‐tumour efficacy on glioma models of <scp>PHA</scp>‐848125, a multi‐kinase inhibitor able to cross the blood–brain barrierClara Albanese, Marina Ciomei, Rachele Alzani et al.|British Journal of Pharmacology|2013Cited by 21
NMS-P088, a CSF-1R, FLT3 and KIT inhibitor with outstanding activity on gatekeeper resistance mutations, high tolerability, and potential for combination therapiesElena Ardini, Marina Ciomei, Andrea Borgia et al.|European Journal of Cancer|2016Cited by 1